Compare ADMA Biologics Inc (ADMA) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Marsh & McLennan Companies, Inc. — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Marsh & McLennan Companies, Inc. trades at $179.17 (market cap $85.76B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 40.3× ADMA Biologics Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.02% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MRSH | |
|---|---|---|
Market Cap | $2.13B | $85.76B |
Sector | Health | Financials |
52-Week High | $20.38 | $214.71 |
52-Week Low | $7.60 | $157.32 |
Enterprise Value | $2.20B | $106.60B |
Dividend Yield | — | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Marsh (MRSH) trades at $178.00, showing modest daily weakness (-0.3%) but maintaining a bullish technical trend above key support levels. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.29 exceeding expectations, and robust profitability metrics with 14.26% net income margin and 27.42% ROE. Recent acquisition of TriBridge Partners strengthens advisory capabilities while dividend payments provide shareholder returns.
Marsh presents a compelling investment case with analyst consensus target of $192.00 offering 7.9% upside potential. The stock trades at reasonable valuation multiples (P/E 21.84, P/S 3.12) for its quality profile, though rising costs and premium valuation warrant monitoring. Institutional sentiment remains positive with 11 buy ratings outweighing 1 sell recommendation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
